ZANTE GREG (Chief Financial Officer) sold 7.9% of their position (16.14K shares) of VIKING THERAPEUTICS, INC. on the open market
Open‑market sale worth $922.2K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock, par value $0.00001 per share
Shares
+6.67K
Price / share
—
Trade value
—
% of position
Common Stock, par value $0.00001 per share
Shares
+21.67K
Price / share
—
Trade value
—
% of position
Common Stock, par value $0.00001 per share
Shares
−12.66K
Price / share
$56.96
Trade value
$721.23K
% of position
Common Stock, par value $0.00001 per share
Shares
−2.97K
Price / share
$57.71
Trade value
$171.63K
% of position
Common Stock, par value $0.00001 per share
Shares
−500.00
Price / share
$58.71
Trade value
$29.36K
% of position
Net shares
+12.20K
Net value
-$922.21K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per share Direct | 7/29/2024 | A · Award | +6.67K | — | — | 3.8% | 174.85K | 181.52K |
| Common Stock, par value $0.00001 per share Direct | 7/29/2024 | A · Award | +21.67K | — | — | 11.9% | 181.52K | 203.19K |
| Common Stock, par value $0.00001 per share Direct | 7/30/2024 | S · Sale | −12.66K | $56.96 | $721.23K | 6.2% | 203.19K | 190.53K |
| Common Stock, par value $0.00001 per share Direct | 7/30/2024 | S · Sale | −2.97K | $57.71 | $171.63K | 1.6% | 190.53K | 187.55K |
| Common Stock, par value $0.00001 per share Direct | 7/30/2024 | S · Sale | −500.00 | $58.71 | $29.36K | 0.3% | 187.55K | 187.05K |
| Total | +12.20K | -$922.21K | ||||||